CN106380480A - 2-oxobutyric acid p-nitrobenzoyl hydrazone dibenzyl tin complex and preparation method and application thereof - Google Patents

2-oxobutyric acid p-nitrobenzoyl hydrazone dibenzyl tin complex and preparation method and application thereof Download PDF

Info

Publication number
CN106380480A
CN106380480A CN201610751473.4A CN201610751473A CN106380480A CN 106380480 A CN106380480 A CN 106380480A CN 201610751473 A CN201610751473 A CN 201610751473A CN 106380480 A CN106380480 A CN 106380480A
Authority
CN
China
Prior art keywords
coordination compound
alpha
nitrophenyl formyl
stannous phenide
ketobutyric acid
Prior art date
Application number
CN201610751473.4A
Other languages
Chinese (zh)
Other versions
CN106380480B (en
Inventor
谭宇星
蒋伍玖
庾江喜
朱小明
张志坚
邝代治
张复兴
Original Assignee
衡阳师范学院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 衡阳师范学院 filed Critical 衡阳师范学院
Priority to CN201610751473.4A priority Critical patent/CN106380480B/en
Publication of CN106380480A publication Critical patent/CN106380480A/en
Application granted granted Critical
Publication of CN106380480B publication Critical patent/CN106380480B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22Tin compounds
    • C07F7/2284Compounds with one or more Sn-N linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22Tin compounds
    • C07F7/2296Purification, stabilisation, isolation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

The invention discloses a 2-oxobutyric acid p-nitrobenzoyl hydrazone dibenzyl tin complex, which is a complex having the structural formula (I) as shown in the specification. In the structural formula (I), R is phenyl group. The invention also discloses a preparation method of the 2-oxobutyric acid p-nitrobenzoyl hydrazone dibenzyl tin complex and application of the complex in the preparation of an anti-cancer drug.

Description

A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound and its preparation side Method and application

Technical field

The present invention relates to a kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound and preparation method thereof, and This ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound application in preparing cancer therapy drug.

Background technology

Organotin is the metallo-organic compound that a class contains Sn-C key.Researcher just noticed before very early The Anticancer Activity in vitro of organo-tin compound.The research of organotin (IV) antitumor activity of compound can trace back to nineteen twenty-nine. 1967, Kanisawa etc. thought that stannic chloride is invalid to the primary tumor of mice and rat.But in 1972, Brown found, By food or drug administration by injection, triphenyltin acetate Ph3SnOOCCH3The tumour growth of mice can be suppressed, and triphenyltin chloride Then can not.Between 1972 ~ 1977 years, the substantial amounts of organo-tin compound of Dutch scholar's research, but find no screening valency further The compound of value.They continue deeper into research, finally found that the tin compound of two organic group coordinations, such as tin-oxide (R2SnO), stannum hydroxide [ SnR2(OH) X ] etc. have anti-tumor activity, and find out that they all contain or hydrolyze and can produce stannum oxygen Key.1986, Crowe etc. was found that some organo-tin compounds have preferable active anticancer again, from this, resisted with regard to organotin The research of cancer activity becomes another extremely active focus after cisplatin.1989, American National anticancer research institute (National Cancer Institute) has carried out antitumor activity screening, result table to more than 2,000 kinds of organo-tin compounds Some organo-tin compounds bright have inhibitory action to P388 Lymphocytic leukemia.2002, Gielen et al. was to organic The activity of stannum carboxylate compound has done comprehensive summing up, thinks that many organo-tin compounds have really preferably external after research Active anticancer.

Research shows, the organic group that organic tin atom connects and the part participating in being coordinated decide organo-tin compound Biological activity, select some to have the tin atom in organic ligand and the organotin of good biological activity in itself and be coordinated and cause The great interest of people.Acylhydrazone is by a class Schiff compound of hydrazide kind compound modification, they Formed by aldehydes or ketones and hydrazides condensation, there is in molecule the of bonding similar with peptide bond, there is good biological activity, stronger joining Capability and various coordination mode, and have a wide range of applications at aspects such as medicine, pesticide, material and analytical reagents.Closely Nian Lai, both at home and abroad many research worker it is compared in terms of biological activity and in depth studies, research finds acylhydrazone class Compound has the various active such as anticancer, sterilization, antiinflammatory.Therefore, acylhydrazone class Schiff part is combined with organotin it is intended to Obtain the higher noval chemical compound of biological activity, become people's research direction interested.

Chinese patent CN 102718794A discloses a kind of pair of acylhydrazone class Schiff stannous phenide coordination compound and its in system Application in standby Antilung gland cancer, colon cancer, the medicine of leukaemia.

Chinese patent CN 101851251A disclose a kind of dibutyl tin coordination compound of acylhydrazone class Schiff part and its Application in preparation treatment hepatocarcinoma, adenocarcinoma of lung, breast carcinoma, carcinoma of prostate, colon cancer or early children's leukemic medicine of grain.

Document (Journal of Organometallic Chemistry, 2014,75:83-91) report, organotin Acylhydrazone class Schiff base complex is thin to human colon cancer cell (HCT-116), human lung adenocarcinoma cell (A549), human umblilical vein endothelial Born of the same parents (HUVEC) have compared with strong biological activity, and are better than carboplatin.

Document (Journal of Organometallic Chemistry, 2013,724:23-31) report, series has Machine stannum acylhydrazone class Schiff base complex, organo-tin compound and acylhydrazone class Schiff part are respectively to human lung adenocarcinoma cell (A549), the inhibitory action of the cancerous cell such as human colon cancer cell (HCT-8), people in loop (hl-60).

Document (Bioorganic & Medicinal Chemistry Letters, 2015,25: 4461- 4463) Report, the active anticancer to human liver cancer cell (HuH-7) and human lung adenocarcinoma cell (A549) for multiple acylhydrazone class Schiff parts.

Document (Journal of Organometallic Chemistry, 2016,864:48-58) report, two hydrocarbon Base stannum acylhydrazone class Schiff base complex is to human lung adenocarcinoma cell (A549), human cervical carcinoma cell (HeLa), human breast cancer cell (MCF-7) inhibitory action of cancerous cell such as.

It is to the experiment proved that the material with active anticancer based on acylhydrazone class Schiff organotin complex, the present invention selects Select p-nitrobenzoylhydrazide, 2-butanone acid is reacted under certain condition with diphenyl stannum dichloride, synthesis has obtained to human lung cancer Cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7) have the coordination compound of certain inhibitory activity, for opening Send out cancer therapy drug and provide new approach.

Content of the invention

The first object of the present invention there is provided a kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.

The second object of the present invention is to provide above-mentioned ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound preparation Method.

The third object of the present invention is to provide above-mentioned ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound in system Application in standby cancer therapy drug.

As a kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of a first aspect of the present invention, for knot The coordination compound of structure formula (I)

(I)

Wherein R is phenyl.

The ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of the present invention is through elementary analysiss, infrared spectrum, core Magnetic resonance spectrum and X-ray single crystal diffraction structural analyses, result is as follows:

Elementary analysiss (C48H46N6O12Sn2):Value of calculation:C 50.73, H 4.08, N 7.40;Measured value:C 50.82, H 4.11, N 7.45.

FT-IR (KBr, ν/cm-1): 3506, 3057, 2972, 2937, 1687, 1597, 1529, 1431, 1338, 804, 717, 688, 588, 551, 453, 416.

1H NMR (500 MHz, CDCl3, δ/ppm): 8.49 (d,J=8.8 Hz, 2H), 8.34 (d,J=8.8 Hz, 2H), 7.79-7.81 (m, 4H), 7.47-7.51 (m, 6H), 3.12-3.17 (q,J=7.6 Hz, 2H), 1.33 (t,J=7.6 Hz, 3H).

13C NMR (126 MHz, CDCl3, δ/ppm): 172.73, 162.82, 162.67, 150.33, 138.03, 136.04, 135.34, 131.66, 129.67, 129.57, 123.81, 21.48, 10.83.

119Sn NMR (187 MHz, CDCl3, δ/ppm): -294.66.

The ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of the present invention is crystal structure, and its crystal is monocline Crystallographic system, space group P2 (1)/n, a=1.2375 (6) nm, b=1.1479 (6) nm, c=1.6659 (8) nm, α=γ =90 °, β=100.266 (7) °, Z=2, V=2.328 (2) nm3, Dc=1.621 Mg m-3, m (MoK α)=1.143 mm-1, F (000)=1144.

Being structurally characterized in that of the ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of the present invention:In molecule, stannum is former Son is seven coordination distortion pentagonal bipyramid configurations.

The ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of the present invention has certain thermally-stabilised scope, Less than 220 DEG C can stable existence.

System as a kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of a second aspect of the present invention Preparation Method, adds diphenyl stannum dichloride, p-nitrobenzoylhydrazide, 2-butanone sour and molten in the reaction vessel having nitrogen protection Agent absolute methanol, reacts 5 ~ 24 h, cooling under conditions of temperature is 45 ~ 65 DEG C, filters, control under conditions of 20 ~ 35 DEG C Solvent volatilization crystallization, obtains yellow transparent crystal, as ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.

The preparation characteristic of the ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of the present invention is:From relatively easy The raw material being easy to get sets out, and without the separation of intermediate, directly obtains baroque molecule, i.e. one kettle way;Such reaction exists Economically with environmental friendliness on advantageously.

In a preferred embodiment of the invention, described diphenyl stannum dichloride, p-nitrobenzoylhydrazide, 2-butanone acid The amount of the material of three is than for 1:(1~1.05):(1.05~1.15).

In a preferred embodiment of the invention, described solvent absolute methanol consumption is every mM of diphenyl dichloride Stannum adds 15 ~ and 35 milliliters.

A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound as a third aspect of the present invention is being made Application in standby cancer therapy drug.

Applicant has carried out Anticancer Activity in vitro to above-mentioned ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound Determine research it is thus identified that ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound has certain anticancer bioactive, That is the purposes of above-mentioned coordination compound is the application in preparing cancer therapy drug, be exactly specifically prepare anti-human pulmonary carcinoma, Application in human liver cancer and human breast carcinoma medicine.

The ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of the present invention is to human lung carcinoma cell, human liver cancer cell Show good active anticancer with human breast cancer cell, the ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide of the present invention is joined The features such as compound active anticancer height, low cost, preparation method are simple, the cancer therapy drug for developing new provides new way.

Brief description

Fig. 1 is the IR spectrogram of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.

Fig. 2 is ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound1H NMR spectra.

Fig. 3 is ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound13C NMR spectra.

Fig. 4 is ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound119Sn NMR spectra.

Fig. 5 is the crystal structure figure of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.

Fig. 6 is the TG-DTG curve of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.

Specific embodiment

By detailed description below, the present invention is described in further detail.

Embodiment 1:

The preparation of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound:

0.344g (1.0mmol) diphenyl stannum dichloride, 0.181g is added in the 100mL there-necked flask having nitrogen protection (1.0mmol) p-nitrobenzoylhydrazide, the acid of 0.112g (1.1mmol) 2-butanone and 15mL solvent absolute methanol, are 45 in temperature 8 h are reacted under conditions of ~ 65 DEG C, cooling, filter, control solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtain yellow transparent brilliant Body, as ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.Yield:81.1%.Fusing point:220~222℃(dec).

Elementary analysiss (C48H46N6O12Sn2):Value of calculation:C 50.73, H 4.08, N 7.40;Measured value:C 50.82, H 4.11, N 7.45.

FT-IR (KBr, ν/cm-1): 3506, 3057, 2972, 2937, 1687, 1597, 1529, 1431, 1338, 804, 717, 688, 588, 551, 453, 416.

1H NMR (500 MHz, CDCl3, δ/ppm): 8.49 (d,J=8.8 Hz, 2H), 8.34 (d,J=8.8 Hz, 2H), 7.79-7.81 (m, 4H), 7.47-7.51 (m, 6H), 3.12-3.17 (q,J=7.6 Hz, 2H), 1.33 (t,J=7.6 Hz, 3H).

13C NMR (126 MHz, CDCl3, δ/ppm): 172.73, 162.82, 162.67, 150.33, 138.03, 136.04, 135.34, 131.66, 129.67, 129.57, 123.81, 21.48, 10.83.

119Sn NMR (187 MHz, CDCl3, δ/ppm): -294.66.

Crystallographic data:Monoclinic system, space group P2 (1)/n, a=1.2375 (6) nm, b=1.1479 (6) nm, c =1.6659 (8) nm, α=γ=90 °, β=100.266 (7) °, Z=2, V=2.328 (2) nm3, Dc=1.621 Mg·m-3, m (MoK α)=1.143 mm-1, F (000)=1144.

Embodiment 2:

The preparation of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound:

0.344g (1.0mmol) diphenyl stannum dichloride, 0.181g is added in the 100mL there-necked flask having nitrogen protection (1.0mmol) p-nitrobenzoylhydrazide, the acid of 0.107g (1.05mmol) 2-butanone and 35mL solvent absolute methanol, in temperature be 5 h are reacted under conditions of 45 ~ 65 DEG C, cooling, filter, control solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtain yellow transparent Crystal, as ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.Yield:86.5%.Fusing point:220~222℃ (dec).

Elementary analysiss (C48H46N6O12Sn2):Value of calculation:C 50.73, H 4.08, N 7.40;Measured value:C 50.82, H 4.11, N 7.45.

FT-IR (KBr, ν/cm-1): 3506, 3057, 2972, 2937, 1687, 1597, 1529, 1431, 1338, 804, 717, 688, 588, 551, 453, 416.

1H NMR (500 MHz, CDCl3, δ/ppm): 8.49 (d,J=8.8 Hz, 2H), 8.34 (d,J=8.8 Hz, 2H), 7.79-7.81 (m, 4H), 7.47-7.51 (m, 6H), 3.12-3.17 (q,J=7.6 Hz, 2H), 1.33 (t,J=7.6 Hz, 3H).

13C NMR (126 MHz, CDCl3, δ/ppm): 172.73, 162.82, 162.67, 150.33, 138.03, 136.04, 135.34, 131.66, 129.67, 129.57, 123.81, 21.48, 10.83.

119Sn NMR (187 MHz, CDCl3, δ/ppm): -294.66.

Crystallographic data:Monoclinic system, space group P2 (1)/n, a=1.2375 (6) nm, b=1.1479 (6) nm, c =1.6659 (8) nm, α=γ=90 °, β=100.266 (7) °, Z=2, V=2.328 (2) nm3, Dc=1.621 Mg·m-3, m (MoK α)=1.143 mm-1, F (000)=1144.

Embodiment 3:

The preparation of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound:

0.344g (1.0mmol) diphenyl stannum dichloride, 0.190g is added in the 100mL there-necked flask having nitrogen protection (1.05mmol) p-nitrobenzoylhydrazide, the acid of 0.117g (1.15mmol) 2-butanone and 25mL solvent absolute methanol, in temperature be 24 h are reacted under conditions of 45 ~ 65 DEG C, cooling, filter, control solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtain yellow saturating Bright crystal, as ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.Yield:85.4%.Fusing point:220~222℃ (dec).

Elementary analysiss (C48H46N6O12Sn2):Value of calculation:C 50.73, H 4.08, N 7.40;Measured value:C 50.82, H 4.11, N 7.45.

FT-IR (KBr, ν/cm-1): 3506, 3057, 2972, 2937, 1687, 1597, 1529, 1431, 1338, 804, 717, 688, 588, 551, 453, 416.

1H NMR (500 MHz, CDCl3, δ/ppm): 8.49 (d,J=8.8 Hz, 2H), 8.34 (d,J=8.8 Hz, 2H), 7.79-7.81 (m, 4H), 7.47-7.51 (m, 6H), 3.12-3.17 (q,J=7.6 Hz, 2H), 1.33 (t,J=7.6 Hz, 3H).

13C NMR (126 MHz, CDCl3, δ/ppm): 172.73, 162.82, 162.67, 150.33, 138.03, 136.04, 135.34, 131.66, 129.67, 129.57, 123.81, 21.48, 10.83.

119Sn NMR (187 MHz, CDCl3, δ/ppm): -294.66.

Crystallographic data:Monoclinic system, space group P2 (1)/n, a=1.2375 (6) nm, b=1.1479 (6) nm, c =1.6659 (8) nm, α=γ=90 °, β=100.266 (7) °, Z=2, V=2.328 (2) nm3, Dc=1.621 Mg·m-3, m (MoK α)=1.143 mm-1, F (000)=1144.

Embodiment 4:

The preparation of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound:

3.440g (10.0mmol) diphenyl stannum dichloride, 1.864g is added in the 500mL there-necked flask having nitrogen protection (10.3mmol) p-nitrobenzoylhydrazide, the acid of 1.122g (11.0mmol) 2-butanone and 200mL solvent absolute methanol, in temperature For reacting 22 h under conditions of 45 ~ 65 DEG C, cooling, filter, control solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtain yellow Transparent crystal, as ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.Yield:83.7%.Fusing point:220~222℃ (dec).

Elementary analysiss (C48H46N6O12Sn2):Value of calculation:C 50.73, H 4.08, N 7.40;Measured value:C 50.82, H 4.11, N 7.45.

FT-IR (KBr, ν/cm-1): 3506, 3057, 2972, 2937, 1687, 1597, 1529, 1431, 1338, 804, 717, 688, 588, 551, 453, 416.

1H NMR (500 MHz, CDCl3, δ/ppm): 8.49 (d,J=8.8 Hz, 2H), 8.34 (d,J=8.8 Hz, 2H), 7.79-7.81 (m, 4H), 7.47-7.51 (m, 6H), 3.12-3.17 (q,J=7.6 Hz, 2H), 1.33 (t,J=7.6 Hz, 3H).

13C NMR (126 MHz, CDCl3, δ/ppm): 172.73, 162.82, 162.67, 150.33, 138.03, 136.04, 135.34, 131.66, 129.67, 129.57, 123.81, 21.48, 10.83.

119Sn NMR (187 MHz, CDCl3, δ/ppm): -294.66.

Crystallographic data:Monoclinic system, space group P2 (1)/n, a=1.2375 (6) nm, b=1.1479 (6) nm, c =1.6659 (8) nm, α=γ=90 °, β=100.266 (7) °, Z=2, V=2.328 (2) nm3, Dc=1.621 Mg·m-3, m (MoK α)=1.143 mm-1, F (000)=1144.

Test example:

The ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of the present invention, it is to pass through that its Anticancer Activity in vitro measures MTT experiment method is realized.

MTT analytic process:

With metabolism reduction 3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide it is Basis.Succinate dehydrogenase in living cells mitochondria can make exogenous MTT be reduced to water-insoluble bluish violet crystallization first a ceremonial jade-ladle, used in libation (Formazan) and be deposited in cell, and dead cell no this function.Dimethyl sulfoxide (DMSO) can dissolve the first a ceremonial jade-ladle, used in libation in cell, Measure the optical density of characteristic wavelength with microplate reader, can indirectly reflect living cells quantity.

To measure the ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound pair of embodiment 1 preparation using mtt assay The inhibitory activity of human lung carcinoma cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7).

Cell strain and cultivating system:H460, HepG2 and MCF7 cell strain takes from American. tissue incubator (ATCC).With containing RPMI 1640 (GIBICO company) culture medium of 10% hyclone, in 5% (volume fraction) CO2, 37 DEG C of saturated humidity incubators Inside carry out In vitro culture.

Test process:Test medicinal liquid (1nM ~ 10 μM) is added separately in each hole according to the Concentraton gradient of concentration, often Individual concentration sets 6 parallel holes.Experiment is divided into drug study group (being separately added into the test medicine of variable concentrations), matched group (only to add training Nutrient solution and cell, are not added with testing medicine) and blank group (only adding culture medicine, be not added with cell and test medicine).Orifice plate after dosing is put In 37 DEG C, 5%CO272h is cultivated in incubator.The activity of control drug measures according to the method for test sample.Cultivating 72h In orifice plate afterwards, every hole adds MTT 40 μ L (being made into 4mg/mL with D-Hanks buffer).After placing 4h at 37 DEG C, remove upper strata Clear liquid.Every hole adds 150 μ L DMSO, vibrates 5min, makes Formazan crystallize dissolving.Finally, using automatic microplate reader in 570nm The optical density in each hole is detected at wavelength.

Data processing:Data processing uses Graph Pad Prism version 7.0 program, coordination compound IC50By journey The nonlinear regression model (NLRM) in sequence with S-shaped dose response is fitted obtaining.

Thin to human lung carcinoma cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7) with MTT analytic process Born of the same parents' strain is analyzed, and measures its IC50Value, as shown in table 1, conclusion is result:From data in table, with the 2- carbonyl of the present invention Butanoic acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound is used as cancer therapy drug, to human lung carcinoma cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7) has certain drug effect, can be used as the candidate compound of cancer therapy drug.

Table 1 ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound cancer therapy drug external activity test data.

Human lung cancer Human liver cancer Human breast carcinoma Cell strain H460 HepG2 MCF7 IC50(μM) 1.67±0.07 2.74±0.15 0.86±0.12

The ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound of remaining embodiment preparation is with mtt assay to human lung cancer The same test example of active anticancer method of testing of cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7), surveys Test result is essentially identical with table 1.

These are only the preferred embodiments of the present invention and test example, be not limited to the present invention it is clear that the skill of this area Art personnel can carry out various changes, modification without departing from the spirit and scope of the present invention to the present invention.If to the present invention's These modifications and modification belong within the scope of the claims in the present invention and its equivalent technologies, belong to the protection model of the present invention Enclose.

Claims (9)

1. a kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound, for the coordination compound of following structure formula (I):
(I)
Wherein R is phenyl.
2. contain a kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound as claimed in claim 1, it is infrared Spectroscopic data:FT-IR (KBr, ν/cm-1): 3506, 3057, 2972, 2937, 1687, 1597, 1529, 1431, 1338, 804, 717, 688, 588, 551, 453, 416;Its nuclear-magnetism modal data:1H NMR (500 MHz, CDCl3, δ/ppm): 8.49 (d,J=8.8 Hz, 2H), 8.34 (d,J=8.8 Hz, 2H), 7.79-7.81 (m, 4H), 7.47-7.51 (m, 6H), 3.12-3.17 (q,J=7.6 Hz, 2H), 1.33 (t,J=7.6 Hz, 3H);13C NMR (126 MHz, CDCl3, δ/ppm): 172.73, 162.82, 162.67, 150.33, 138.03, 136.04, 135.34, 131.66, 129.67, 129.57, 123.81, 21.48, 10.83;119Sn NMR (187 MHz, CDCl3, δ/ppm): -294.66.
3. ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound as claimed in claim 1, wherein, described 2- Carbonyl butanoic acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound is crystal structure, and its crystallographic data is as follows:Monoclinic system, space Group P2 (1)/n, a=1.2375 (6) nm, b=1.1479 (6) nm, c=1.6659 (8) nm, α=γ=90 °, β= 100.266 (7) °, Z=2, V=2.328 (2) nm3, Dc=1.621 Mg m-3, m (MoK α)=1.143 mm-1, F (000)= 1144;In molecule, tin atom is seven coordination distortion pentagonal bipyramid configurations.
4. described in claim 1, ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound has certain thermally-stabilised model Enclose, can stable existence below 220 DEG C.
5. the preparation method of the ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound described in claim 1, its feature It is to add diphenyl stannum dichloride, p-nitrobenzoylhydrazide, 2-butanone acid and solvent in the reaction vessel having nitrogen protection no Water methanol, reacts 5 ~ 24 h, cooling under conditions of temperature is 45 ~ 65 DEG C, filters, and controls solvent under conditions of 20 ~ 35 DEG C Volatilization crystallization, obtains yellow transparent crystal, as ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound.
6. the method for preparation as claimed in claim 5 is it is characterised in that described diphenyl stannum dichloride, p-nitrophenyl formyl Hydrazine, the amount ratio of the material of 2-butanone acid three are for 1:(1~1.05):(1.05~1.15).
7. the method for preparation as claimed in claim 5 is it is characterised in that described solvent absolute methanol consumption is every mM two Phenyl dichloro stannum adds 15 ~ and 35 milliliters.
8. the answering in preparing cancer therapy drug of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide coordination compound described in claim 1 With.
9. the application described in claim 8, wherein said cancerous cell is human lung carcinoma cell, human liver cancer cell, human breast cancer cell.
CN201610751473.4A 2016-08-30 2016-08-30 A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide complex and its preparation method and application CN106380480B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610751473.4A CN106380480B (en) 2016-08-30 2016-08-30 A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide complex and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610751473.4A CN106380480B (en) 2016-08-30 2016-08-30 A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide complex and its preparation method and application

Publications (2)

Publication Number Publication Date
CN106380480A true CN106380480A (en) 2017-02-08
CN106380480B CN106380480B (en) 2018-11-27

Family

ID=57916178

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610751473.4A CN106380480B (en) 2016-08-30 2016-08-30 A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide complex and its preparation method and application

Country Status (1)

Country Link
CN (1) CN106380480B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060869A (en) * 2010-12-14 2011-05-18 聊城大学 Tindiphenyl (IV) coordination compound of benzoylformic acid-3-hydroxyl-2-naphthyl formyl hydrazone as well as preparation method and application thereof
CN105198921A (en) * 2015-11-11 2015-12-30 衡阳师范学院 2-carbonyl-2-phenylacetic acid salicyloyl hydrazone dibutyltin complex as well as preparation method and application of 2-carbonyl-2-phenylacetic acid salicyloyl hydrazone dibutyltin complex
CN105348318A (en) * 2015-11-11 2016-02-24 衡阳师范学院 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060869A (en) * 2010-12-14 2011-05-18 聊城大学 Tindiphenyl (IV) coordination compound of benzoylformic acid-3-hydroxyl-2-naphthyl formyl hydrazone as well as preparation method and application thereof
CN105198921A (en) * 2015-11-11 2015-12-30 衡阳师范学院 2-carbonyl-2-phenylacetic acid salicyloyl hydrazone dibutyltin complex as well as preparation method and application of 2-carbonyl-2-phenylacetic acid salicyloyl hydrazone dibutyltin complex
CN105348318A (en) * 2015-11-11 2016-02-24 衡阳师范学院 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIN HONG等,: "Weakly-bridged dimeric diorganotin(IV) compounds derived from pyruvic acid hydrazone Schiff base ligands: Synthesis, characterization and crystal structures", 《SOLID STATE SCIENCES》 *

Also Published As

Publication number Publication date
CN106380480B (en) 2018-11-27

Similar Documents

Publication Publication Date Title
Kalaivani et al. Influence of terminal substitution on structural, DNA, protein binding, anticancer and antibacterial activities of palladium (II) complexes containing 3-methoxy salicylaldehyde-4 (N) substituted thiosemicarbazones
CN101503423B (en) Parachlorobenzoyl hydrazone organotin complex, preparation and use
Root et al. Structural and spectroscopic characterization of dioxovanadium (V) complexes with asymmetric Schiff base ligands
Parish et al. Chemical and biological studies of dichloro (2-((dimethylamino) methyl) phenyl) gold (III)
Panchal et al. Bactericidal activity of different oxovanadium (IV) complexes with Schiff bases and application of chelation theory
Vujić et al. Palladium (II) complexes with R2edda derived ligands. Part IV. O, O′-dialkyl esters of (S, S)-ethylenediamine-N, N′-di-2-(4-methyl)-pentanoic acid dihydrochloride and their palladium (II) complexes: Synthesis, characterization and in vitro antitumoral activity against chronic lymphocytic leukemia (CLL) cells
Li et al. Synthesis and antitumor activity of a new mixed-ligand complex di-n-butyl-(4-chlorobenzohydroxamato) tin (IV) chloride
Hussain et al. Synthesis, characterization, biological activities, crystal structure and DNA binding of organotin (IV) 5-chlorosalicylates
Ferreira et al. Synthesis, characterization and antifungal activity of new dithiocarbamate-based complexes of Ni (II), Pd (II) and Pt (II)
CN102060869A (en) Tindiphenyl (IV) coordination compound of benzoylformic acid-3-hydroxyl-2-naphthyl formyl hydrazone as well as preparation method and application thereof
Manna et al. New insights on the active species and mechanism of cytotoxicity of salan-Ti (IV) complexes: A stereochemical study
CN103396436B (en) Monobutyltin substituted salicylic aldehydes contracting arylamine Schiff base complex and preparation method and application
CN101838284B (en) Dibutyltin oxide coordination compound and preparation method and application thereof
Cotton et al. The lengths of molybdenum to molybdenum quadruple bonds: Correlations, explanations, and corrections
Tirkey et al. Synthesis, characterization and antibacterial studies of ferrocenyl and cymantrenyl hydrazone compounds
Guo et al. Stereoselective formation of seven-coordinate titanium (IV) monomer and dimer complexes of ethylenebis (o-hydroxyphenyl) glycine
CN105384702B (en) Three substitution s-triazine compounds and preparation method thereof
Holló et al. Synthesis, characterisation and antimicrobial activity of bis (phthalazine-1-hydrazone)-2, 6-diacetylpyridine and its complexes with CoIII, NiII, CuII and ZnII
Kalita et al. Synthesis, crystal structure, bioactivities of Ni (II), Cu (II), Co (II) and Pd (II) complexes with unsymmetrical thioether donor Schiff base: Phosphine free Pd (II) complex catalyzed Suzuki reaction
Naseri et al. First row transition metal complexes of thienyl substituted terpyridine: Structural, photophysical and biological studies
Mondal et al. Synthesis, structure and solution chemistry of dioxidovanadium (V) complexes with a family of hydrazone ligands. Evidence of formation of centrosymmetric dimers via H-bonds in the solid state
CN105198921B (en) A kind of 2- carbonyl -2- phenylacetic acid salicyloyl hydrazone dibutyl tin complex and its preparation method and application
Daniel Thangadurai et al. Synthesis and characterisation of ruthenium (III) complexes containing monobasic bidentate Schiff bases and their biological activities
CN101037447B (en) Metal complex using plumbagin as ligand, synthesizing method and usage thereof
Hosny et al. Schiff base complexes derived from 2-acetylpyridine, leucine, and some metal chlorides: their preparation, characterization, and physical properties

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant